36 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
29
Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.
Xenon Pharmaceuticals
39
4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.
Janssen Research and Development
27
Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases.
Xenon Pharmaceuticals
28
Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects.
Xenon Pharmaceuticals
36
Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization.
Sanofi-Aventis Deutschland
57
Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.
Xenon Pharmaceuticals
5
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
Merck Frosst Centre For Therapeutic Research
36
Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors.
Abbott Laboratories
9
Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series.
Merck Frosst Centre For Therapeutic Research
21
Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.
Merck Frosst Centre For Therapeutic Research
10
Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.
Merck Frosst Centre For Therapeutic Research
20
Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.
Merck Frosst Centre For Therapeutic Research
19
Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.
Merck Frosst Centre For Therapeutic Research
11
Discovery of novel SCD1 inhibitors: 5-alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4'-piperidine] analogs.
Daiichi Sankyo
15
N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.
Pfizer
10
Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.
Daiichi Sankyo
42
2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.
Merck Frosst Centre For Therapeutic Research
23
SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.
Merck Frosst Centre For Therapeutic Research
29
Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine].
Daiichi Sankyo
20
Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats.
Daiichi Sankyo
10
Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.
Merck Frosst Centre For Therapeutic Research
18
Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
Gilead Sciences
29
Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.
Daiichi Sankyo
20
Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.
Daiichi Sankyo
24
Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
Cv Therapeutics
40
Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors.
Cv Therapeutics
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.
Johann Wolfgang Goethe University
147
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
Central South University
47
Tumor-Activated Benzothiazole Inhibitors of Stearoyl-CoA Desaturase.
Ut Southwestern Medical Center
52
Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
Japan Tobacco
18
Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents.
Takeda Pharmaceutical
28
Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors.
Karolinska Institutet
90
Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
Repare Therapeutics
50
Substituted piperidines thiazolyl acetamides as glycosidase inhibitors and uses thereof
Alectos Therapeutics
11
Carbamoylcholine homologs: novel and potent agonists at neuronal nicotinic acetylcholine receptors.
The Danish University of Pharmaceutical Sciences